{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit was not calculable because an insufficient number of participants reached the event at the final time point for assessment","groupId":"OG000","lowerLimit":"12.1","upperLimit":"NA","value":"28.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Progression free survival (PFS) was defined as the time from registration to hematologic progression or death of any cause. Progression free and alive patients were censored at the date of last follow-up. The median PFS with 95% CI was estimated using the Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide (Len) 15mg daily (days 1-21); Cyclophosphamide (Cyc) 300 mg/m\\^2 (days 1, 8, 15); Dexamethasone (Dex) 40 mg weekly","id":"OG000","title":"Len/Cyc/Dex"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Duration of study (up to 3 years)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}